Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963948 · ClinicalTrials.gov registry record
A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3
A clinical trial of Substance Abuse, sponsored by NYU Langone Health.
- Completed
- Registry status
- 113,123
- Enrollment target
- 2
- Study locations
NCT02963948 is a study of Substance Abuse that has completed, run by NYU Langone Health. The registered enrollment target is 113,123 participants, above the 3,309-participant average among 58 other Substance Abuse trials with a reported enrollment target (3319% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT02963948, a study of Substance Abuse, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 113,123 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropriate interventions by providing clinical decision support (CDS) and a mechanism for making referrals to addiction treatment. Investigators aim to maximize the efficient adoption of screening, CDS, and treatment referrals by integrating all of these activities into the electronic health record (EHR). The study will be conducted at three sites, representing three large health systems. Each phase will include deliverables essential to move to the next phase, and an independent Advisory Committee will review progress and make recommendations at each transition about how best to progress to each subsequent phase. Based on progress during earlier phases, the Advisory Committee may recommend expansion to additional clinics or health systems during the second part of Phase 4.
Conditions Studied
Interventions
- BEHAVIORAL Meetings with implementation leader(s)
- BEHAVIORAL the SAAS survey
- BEHAVIORAL Patient surveys
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113,123 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2019-09-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963948
The ClinicalTrials.gov registry entry for NCT02963948 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 113,123 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,309-participant average among 58 other Substance Abuse trials with a reported enrollment target (3319% higher). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 3 interventions - of which Meetings with implementation leader(s) is the first listed.
NCT02963948 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02963948 about?
NCT02963948 is a clinical study titled "A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3". This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropria...
What is the current status of trial NCT02963948?
This trial is currently completed. The enrollment target is 113,123 participants. The study started on 2018-02-28. Estimated completion is 2019-09-09.
What conditions does trial NCT02963948 study?
This clinical trial studies the following conditions: Substance Abuse.
What interventions are being tested in trial NCT02963948?
The interventions under investigation include: Meetings with implementation leader(s) (BEHAVIORAL), the SAAS survey (BEHAVIORAL), Patient surveys (BEHAVIORAL).
Who is sponsoring clinical trial NCT02963948?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02963948 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Testing ALERT With GTO in Middle Schools
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
The STop UNhealthy Substance Use Now Trial
RECRUITING · NA
-
Substance Abuse Pre-Treatment Screening Study
RECRUITING
-
The Trans-Led Care Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.